Researchers reveal new mechanisms of how fructose promotes colorectal cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Apr-2025 14:08 ET (28-Apr-2025 18:08 GMT/UTC)
A Cancer Research UK-funded trial is giving participants resveratrol as a potential prevention drug for bowel cancer. Resveratrol is a chemical mostly found in red grapes and products made from these grapes, such as wine and juice. Previous lab studies have shown that low doses of purified resveratrol can reach the bowel undigested and inhibit bowel cancer growth.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
This special edition features upcoming oral presentations by MD Anderson researchers at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, providing new insights into the tumor microenvironment and showcasing immunotherapy advances across a variety of cancer types. All SITC content from MD Anderson can be found at MDAnderson.org/SITC.
A Michigan State University researcher’s new model for studying breast cancer could help scientists better understand why and where cancer metastasizes.
Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
The study team found that the investigational vaccine was generally well tolerated and produced an immune response in most patients. The team described the side effects of the vaccine, showed the highest tolerated dose to date, and presented the immunologic effects of the vaccine. Findings are being presented at the Society for Immunotherapy of Cancer Annual Meeting.
Chronic liver disease (CLD) is a growing global health challenge, accounting for millions of deaths each year. Its major contributors include metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease (ALD), and hepatitis C virus infection. These conditions are closely tied to hepatic steatosis, a condition characterized by the abnormal accumulation of fat in the liver. Recent genome-wide association studies have identified the 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) gene and its loss-of-function variant rs72613567, as a significant protective factor against CLD progression, particularly in MASH and ALD. The review highlights the importance of understanding this gene's function to unravel new therapeutic targets.